|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,083,698: Modulators of Immune Checkpoint Protein LAG-3
This report analyzes U.S. Patent 11,083,698, titled "MODULATORS OF IMMUNE CHECKPOINT PROTEIN LAG-3," issued on August 10, 2021. The patent, assigned to Bristol-Myers Squibb Company, claims compositions and methods related to antibodies that target Lymphocyte-Activation Gene 3 (LAG-3). This analysis focuses on the patent's scope, key claims, and the competitive landscape.
What Does U.S. Patent 11,083,698 Claim?
U.S. Patent 11,083,698 covers specific antibodies and their therapeutic uses in modulating the LAG-3 immune checkpoint pathway. LAG-3 is an inhibitory receptor found on T cells, and its blockade can enhance anti-tumor immune responses. The patent's claims define the intellectual property protection surrounding these LAG-3 targeting antibodies.
What are the Key Definitions and Disclosed Embodiments?
The patent defines several critical terms and discloses specific antibody sequences and their properties.
- LAG-3: Defined as Lymphocyte-Activation Gene 3, a protein involved in immune regulation.
- Antibody: The patent specifies antibodies, including fragments thereof, that bind to human LAG-3.
- Epitopes: The claims often define antibodies by their binding to specific epitopes on human LAG-3. While not explicitly listing all epitopes, the patent describes antibodies that bind to conformational epitopes, including those that block the interaction of LAG-3 with its ligands, such as MHC Class II molecules.
- Antibody Sequences: The patent discloses sequences for the variable heavy (VH) and variable light (VL) chains of several specific antibodies. For example, Example 1 describes antibodies designated BMS-986016 (later known as relatlimab) and other related antibodies, providing the full amino acid sequences for their CDRs and framework regions.
- Binding Affinity: The patent claims antibodies with specific binding affinities to human LAG-3. Data in the examples demonstrate high affinity binding, with dissociation constants (Kds) typically in the picomolar to low nanomolar range.
- Functional Activity: Claims are also directed towards antibodies that exhibit specific functional activities, such as blocking the interaction between LAG-3 and its ligands or enhancing T cell activation.
- Compositions: The patent claims pharmaceutical compositions comprising the defined antibodies, formulated with pharmaceutically acceptable carriers.
- Methods of Treatment: A significant portion of the claims covers methods of treating various cancers by administering the claimed antibodies. Cancers mentioned include melanoma, lung cancer, renal cell carcinoma, and colorectal cancer, among others.
What are the Core Claims of the Patent?
The patent's core claims are structured to provide broad protection for the antibodies themselves, their use in therapeutic compositions, and their application in treating diseases.
What are the Key Therapeutic Uses Disclosed?
The patent primarily discloses the use of the claimed LAG-3 antibodies for the treatment of various cancers.
-
Oncology Applications: The central therapeutic application is in oncology. The patent lists a broad range of cancers that can be treated, including:
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Renal cell carcinoma (RCC)
- Colorectal cancer
- Breast cancer
- Prostate cancer
- Ovarian cancer
- Pancreatic cancer
- Glioblastoma
- Leukemia
- Lymphoma
-
Mechanism of Action: The disclosed therapeutic effect stems from the blockade of the LAG-3 inhibitory pathway, which is believed to restore or enhance T cell-mediated anti-tumor immunity.
-
Combination Therapies: The patent explicitly contemplates and claims methods of administering the LAG-3 antibodies in combination with other immunotherapeutic agents. This includes inhibitors of programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1). This combination approach is a significant aspect of the patent's claims, reflecting the emerging understanding of synergistic effects in cancer immunotherapy.
What is the Patent Landscape for LAG-3 Modulators?
The patent landscape for LAG-3 modulators is dynamic, with significant activity from major pharmaceutical companies. U.S. Patent 11,083,698, held by Bristol-Myers Squibb (BMS), is a key patent within this space, particularly given BMS's marketed product, relatlimab (BMS-986016).
Who are the Key Players in the LAG-3 Patent Landscape?
Several companies hold patents related to LAG-3 inhibitors, indicating a competitive R&D environment.
- Bristol-Myers Squibb (BMS): As the assignee of U.S. Patent 11,083,698, BMS is a dominant player. Their lead LAG-3 inhibitor, relatlimab, is approved in combination with nivolumab (Opdivo) for the treatment of unresectable or metastatic melanoma (marketed as Opdualag). The patent's claims directly support this product.
- Merck & Co.: Merck has also developed LAG-3 inhibitors, such as MK-4280. Their patent filings cover antibodies targeting LAG-3 and their therapeutic uses.
- Gilead Sciences: Gilead is active in the immuno-oncology space and has pursued LAG-3 targeting antibodies. Their patent portfolio reflects this focus.
- Regeneron Pharmaceuticals: Regeneron has investigated LAG-3 as a target and holds patents related to antibodies in this class.
- Immutep: This company has a distinct LAG-3 antibody, LAG525, and associated intellectual property.
- Other Biotechs and Pharma: Numerous smaller biotechnology companies and divisions within larger pharmaceutical firms also hold patents or have patent applications pending related to LAG-3 antibodies, epitopes, and therapeutic combinations.
How Does U.S. Patent 11,083,698 Compare to Other LAG-3 Patents?
U.S. Patent 11,083,698 is characterized by its specific antibody sequences and broad therapeutic claims, particularly for combination therapies.
- Specificity: The patent claims specific antibody sequences (e.g., relatlimab). This provides strong protection for that particular molecule. Other patents may claim different antibodies, potentially targeting different epitopes or having different sequence compositions.
- Scope of Claims: The patent includes claims for standalone LAG-3 antibodies and, critically, for combinations with PD-1/PD-L1 inhibitors. This broad scope is valuable in a landscape where combination therapies are increasingly important. Some patents may be narrower, focusing only on specific antibodies or particular therapeutic indications.
- Composition of Matter vs. Method of Use: U.S. Patent 11,083,698 includes both composition of matter claims (for the antibodies) and method of use claims (for treating cancer). Composition of matter claims generally offer stronger, more foundational protection than method of use claims, which can be more susceptible to challenges based on prior art or generic pharmaceutical products.
- Exclusivity: The patent contributes to BMS's market exclusivity for relatlimab and its combinations. Other companies' patents aim to secure their own market positions for their respective LAG-3 programs. The interplay of these patents will influence future market access and the potential for licensing or litigation.
What are the Potential Infringement Risks for Competitors?
Competitors developing LAG-3 inhibitors face potential infringement risks from U.S. Patent 11,083,698, especially if their products are similar to BMS's claimed antibodies or therapeutic methods.
- Structural Similarity: If a competitor's antibody shares significant sequence homology with the antibodies claimed in U.S. Patent 11,083,698, particularly within the CDR regions, direct infringement of composition of matter claims is possible.
- Functional Equivalence: Even if not structurally identical, antibodies that bind to the same or overlapping epitopes and exhibit similar functional characteristics (e.g., blocking LAG-3-ligand interaction, enhancing T cell activity) could be considered infringing under doctrines like the "doctrine of equivalents."
- Combination Therapies: Companies developing LAG-3 inhibitors intended for use in combination with PD-1/PD-L1 inhibitors must carefully review the claims of U.S. Patent 11,083,698. Method of use claims covering such combinations present a significant infringement risk.
- Geographic Scope: Infringement is typically considered within the jurisdiction where the patent is granted (i.e., the United States). Companies operating or marketing products in the U.S. are subject to its patent laws.
What is the Status and Duration of U.S. Patent 11,083,698?
Understanding the patent's status and remaining term is crucial for assessing its commercial impact and potential for future competition.
When Was the Patent Granted and When Does it Expire?
- Grant Date: August 10, 2021.
- Original Expiration: Typically, U.S. patents have a term of 20 years from the filing date. For U.S. Patent 11,083,698, the application filing date was February 2, 2018. Therefore, without any extensions, the patent's original expiration date would be approximately February 2, 2038.
- Patent Term Adjustment (PTA) and Patent Term Extension (PTE): The actual expiration date can be influenced by PTA (to compensate for USPTO delays) and PTE (to compensate for regulatory review delays, particularly for pharmaceuticals). Given the therapeutic nature of the patented invention, it is likely eligible for and may have received or will receive a PTE. The precise expiration date would need to be confirmed through USPTO records or specialized patent databases.
What is the Prosecution History and any Key Rejections/Amendments?
The prosecution history, the record of the application's examination by the USPTO, reveals the challenges and amendments made to secure the patent. While a detailed review of the entire file wrapper is beyond this analysis, common aspects include:
- Prior Art Challenges: Examiners typically cite prior art (existing patents, publications) that may anticipate or render obvious the claimed invention. Amendments are made to distinguish the claimed invention from this prior art.
- Claim Amendments: Claims are often narrowed or rephrased during prosecution to overcome examiner rejections. This might involve more specific definitions of antibodies, epitopes, or functional characteristics. For U.S. Patent 11,083,698, amendments likely focused on defining the specific antibody sequences and their unique binding properties or therapeutic efficacy.
- Examiner Objections: Objections could relate to clarity, enablement, or written description requirements.
What is the Current Status of Litigation or Opposition Proceedings?
As of the latest available public information, significant patent litigation specifically targeting U.S. Patent 11,083,698 has not been widely reported. However, the broader landscape of immuno-oncology patents is subject to ongoing legal scrutiny.
- Potential for Future Litigation: As competitors' products approach the market or gain market share, the likelihood of litigation increases. Companies will assess the strength and scope of this patent in relation to their own products.
- Inter Partes Review (IPR): Competitors could potentially challenge the patent's validity through IPR proceedings at the Patent Trial and Appeal Board (PTAB) if they believe it was granted erroneously based on prior art.
- Enforcement Actions: BMS may proactively enforce its patent rights against perceived infringers.
Key Takeaways
U.S. Patent 11,083,698 is a foundational patent for Bristol-Myers Squibb's LAG-3 franchise, particularly its relatlimab-containing product, Opdualag. The patent claims specific anti-LAG-3 antibodies and their therapeutic applications, including critical combination therapies with PD-1/PD-L1 inhibitors. The patent's strength lies in its specific antibody sequences and broad claims covering compositions and methods of treatment. Competitors in the LAG-3 space face a clear infringement risk, necessitating careful analysis of their own intellectual property and freedom-to-operate. The patent's extended term, potentially through regulatory extensions, ensures a significant period of market exclusivity for BMS.
Frequently Asked Questions
-
What is the primary therapeutic target of the antibodies claimed in U.S. Patent 11,083,698?
The antibodies claimed in U.S. Patent 11,083,698 target the immune checkpoint protein Lymphocyte-Activation Gene 3 (LAG-3).
-
Does U.S. Patent 11,083,698 cover combination therapies?
Yes, the patent includes claims for methods of treating subjects by administering the claimed antibodies in combination with other agents, notably PD-1 or PD-L1 inhibitors.
-
What is the commercial significance of U.S. Patent 11,083,698 for Bristol-Myers Squibb?
This patent is significant as it provides intellectual property protection for relatlimab (BMS-986016), a key component of Bristol-Myers Squibb's immuno-oncology portfolio, particularly for its combination product Opdualag.
-
Can other companies develop LAG-3 inhibitors without infringing U.S. Patent 11,083,698?
Companies can develop LAG-3 inhibitors, but they must ensure their products and methods of use do not infringe on the specific antibody sequences, epitopes, or therapeutic claims outlined in U.S. Patent 11,083,698. This requires a thorough freedom-to-operate analysis.
-
What is the estimated remaining life of U.S. Patent 11,083,698?
With a grant date of August 10, 2021, and an original filing date of February 2, 2018, the patent's original term extends to approximately February 2, 2038. This term may be extended due to Patent Term Adjustments or Patent Term Extensions for regulatory review.
Citations
[1] Bristol-Myers Squibb Company. (2021). U.S. Patent 11,083,698: Modulators of immune checkpoint protein LAG-3. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
